Y. Yang

Five‐year maintenance of clinical response and health‐related quality of life improvements in patients with moderate‐to‐severe psoriasis treated with guselkumab: results from VOYAGE 1 and VOYAGE 2 *

A. Armstrong, C. Griffiths, K. Reich, 2021, The British journal of dermatology.